DZ
DefZone.Net

Kien thuc cong nghe & giai tri

Wiki Article

SDZ-PSD-958

Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net

Xem trên WikipediaBài ngẫu nhiên khác

SDZ-PSD-958
Clinical data
Other namesSDZ PSD 958
Routes of
administration		Unknown[1]
Drug classDopamine D1 and D5 receptor antagonist
ATC code
  • None
Identifiers
  • (4aR,10aR)-4-(4-chloro-2-methylphenyl)-1-methyl-2,3,4a,5,10,10a-hexahydrobenzo[g]quinoxalin-6-ol
PubChem CID
ChemSpider
Chemical and physical data
FormulaC20H23ClN2O
Molar mass342.87 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)Cl)N2CCN([C@H]3[C@H]2CC4=C(C3)C=CC=C4O)C
  • InChI=1S/C20H23ClN2O/c1-13-10-15(21)6-7-17(13)23-9-8-22(2)18-11-14-4-3-5-20(24)16(14)12-19(18)23/h3-7,10,18-19,24H,8-9,11-12H2,1-2H3/t18-,19-/m1/s1
  • Key:VCFAZLUWIBQVRD-RTBURBONSA-N

SDZ-PSD-958 is a selective dopamine D1 and D5 receptor antagonist which was under development for the treatment of psychotic disorders but was never marketed.[1][2] Its route of administration is unknown.[1] The drug has very high affinity for the D1-like receptors (Ki = 0.16–0.20 nM) and more than 400-fold selectivity for these receptors over the D2-like receptors.[2] It has been found to produce hypolocomotion, inhibit dizocilpine (MK-801)-induced hyperlocomotion, inhibit apomorphine-induced rearing, reverse the prolongation of novelty-induced hyperlocomotion by the dopamine D1 receptor agonist CY 208-243, not induce catalepsy, and only weakly inhibit apomorphine-induced stereotyped gnawing in rodents.[2][3] SDZ-PSD-958 was under development by Novartis.[1] It reached the preclinical research stage of development by 1997, whereas no recent development was reported by 2001.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e "SDZ PSD 958". AdisInsight. 25 June 2001. Retrieved 4 June 2026.
  2. ^ a b c Markstein R, Gull P, Rüdeberg C, Urwyler S, Jaton AL, McAllister K, et al. (1996). "SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity". Journal of Neural Transmission. 103 (3). Vienna: 261–276. doi:10.1007/BF01271238. PMID 8739838.
  3. ^ Martin P, Waters N, Waters S, Carlsson A, Carlsson ML (September 1997). "MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride". European Journal of Pharmacology. 335 (2–3): 107–116. doi:10.1016/s0014-2999(97)01188-6. PMID 9369362.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.